Early study tests cancer drug before surgery in head and neck patients
NCT ID NCT00954226
First seen Sep 30, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This early-phase study looked at whether giving the drug erlotinib before surgery could help treat head and neck cancer. 48 patients received either a standard or high dose of the drug, which works by blocking enzymes that help cancer cells grow. The main goal was to measure changes in a protein called phospho-Akt in tumor samples, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEAD AND NECK CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.